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Abstract
Helicobacter pylori infection is considered the most
commonly prevalent gastrointestinal pathogen where it
manages to survive despite the hostile environment of
human stomach, leading to various gastric diseases
including gastric cancer. Due to the chronic inflammatory
state induced by H. pylori and its interaction with host
immune system have diverted researchers to investigate
its correlation with systemic diseases outside of the
gastrointestinal tract. This literature review was done to
explore the association of H. pylori infection with
haematological and cardiovascular diseases. We used
medical subject heading (MeSH) terms "Helicobacter
pylori" with "inflammation," "haematological diseases,"
"coronary heart diseases" or "vascular diseases" to search
PubMed database. All relevant studies identified from
2005 to 2015 were included. As many of the studies are
small-scale or showed weak association, further studies
are needed to address the role of H. pylori in pathogenesis
of haematological and cardiovascular diseases.
Keywords: Helicobacter pylori, Iron deficiency anaemia,
Thrombocytopenia, Coronary heart disease, Host-
immune response.
Introduction
Helicobacter pylori (H. pylori) infects more than 50% of
the world's human population and the bacterium is
highly adaptive to the gastric mucosa.1 H. pyloridamages
the underlying gastric mucosa and initiate a chronic
inflammatory reaction by adhering to the gastric
epithelium which further extends gastric tissue injury. H.
pylori cytotoxin-associated gene A (CagA) translocation
via type IV secretion system into the gastric epithelial cells
induces high levels of inflammatory cytokines such as
tumour necrosis factor-alpha (TNF-α), interleukin (IL)-6, IL-
10 and IL-8.H. pylori infection in the stomach can also
affect the development of various diseases outside the
stomach by eliciting host immune response against the
pathogen binding and chronic inflammation. The H. pylori
vacuolating cytotoxin A (VacA) protein can interact with
lymphocytes, resulting in blockage of IL-2-mediated T cell
proliferation.2 This lymphocyte inhibition and chronic
infection along with the systemic diffusion of various pro-
inflammatory cytokines might influence the remote
organs and result in extra-gastric inflammatory disease
manifestations.
This review was planned to summarise the published
literature from 2005 to 2015. We used medical subject
headings (MeSH) terms such as "Helicobacter pylori" with
"inflammation," "haematological diseases," "Heart
diseases" or "vascular diseases" to search PubMed
database. All relevant studies identified were included
based on study sample size and journal credibility. Studies
pertaining to specific disease association related to H.
pylori infection were described according to various
subheadings as below:
Haematological Diseases
Immune Thrombocytopenia Purpura
Immune thrombocytopenia purpura, also known as
idiopathic thrombocytopenic purpura (ITP), is an
autoimmune disease defined as isolated low blood
platelet count (<100x109/L) and an increased risk of
mucocutaneous bleeding without any apparent cause.3
Systemic reviews found no difference in the prevalence of
H. pylori in adult ITP to un-infected patients, but the
prevalence of H. pylori in children with ITP varied widely
among different populations.4,5 First report on H. pylori
association with haematological disorders, such as ITP,
was described over two decades ago. Since then several
studies from places such as Turkey, Italy and Japan had
reported cases of patients suffering from ITP showed
normalising platelet count after successful eradication of
H. pylori.6,7 A consolidated review of worldwide case
series analysed a total of 1410 H. pylori-infected ITP
patients out of which 56.9% showed recovery in platelet
count to normal after successful H. pylori eradication.8
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Also, another systemic review involving more than 1500
patients reported positive platelet count response
following H. pylori eradication.9 Several hypotheses had
been proposed to explain the role of H. pylori in ITP
development (Figure). This includes molecular mimicry
between antigens and homology of H. pylori Urease B
with platelet surface glycoprotein IIIa leading to platelet
destruction, but the exact mechanism is not completely
understood.6 These studies so far support detection and
eradication of H. pylori as clinically worthwhile approach
in all ITP patients. Also, H. pylori eradication in chronic ITP
patients has been recommended by the Second Asia-
Pacific Consensus Guidelines for H. pylori infection.10
Anaemia Due to Iron Deficiency
Iron deficiency anaemia (IDA) is an anaemia caused due to
very low levels of body stores of iron leading to impaired
erythropoiesis. Peripheral blood smear shows
hypochromic, microcytic red blood cells. Iron deficiency is
the most common cause of anaemia usually due to
nutritional deficiency, severe menstrual blood loss or
gastrointestinal bleeding.11 The role of H. pylori infection
in the pathogenesis of iron restricted anaemia is already
validated and more than 60% of the patients showed
complete recovery from anaemia only after successful H.
pylori eradication.12 A study by Monzon et al. performed
on Spanish adults suffering with chronic IDA showed that
38% patients were infected with H. pylori. In those
patients, anaemia was resolved and iron levels returned to
normal after 6 to 12 months of complete H. pylori
eradication.13 In children, H. pylori infection was
associated with low levels of mean corpuscular
haemoglobin (MCH) along with lower mean corpuscular
value (MCV). In that study, authors also reported that H.
pylori infection status was an indicator of low
haemoglobin and ferritin levels.14 Zuberi et al.15 evaluated
and compared levels of haemoglobin, ferritin and vitamin
B12 in patients from Civil Hospital, Karachi, undergoing
gastrointestinal (GI) endoscopy according to H. pylori
infection status. In this study, the authors confirmed that
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Figure: Pathogenic mechanisms proposed by previous studies to explain the role of Helicobacter pylori in association with haematological and cardiovascular diseases.
H. pylori infection was associated with significantly low
levels of haemoglobin, ferritin and vitamin B12.15
H. pylori might be able to cause iron deficiency by several
mechanisms such as increased loss of iron due to active
haemorrhage secondary to gastritis, peptic ulcer or
gastric cancer; chronic pangastritis resulting in
achlorhydria and reduced iron absorption; reduced
ascorbic acid or iron utilisation by H. pylori itself for
colonisation.16 However, the exact association of H. pylori
with the development of IDA is still not fully understood.
Hepcidin, which is released by hepatocytes, is an essential
regulator of iron metabolism and an acute phase reactant.
Elevated serum levels of hepcidin increases the
breakdown of iron transporter protein, ultimately
inhibiting iron uptake. Moreover, increased levels of
serum pro-hepcidin were reported in H. pylori infected
anaemia patients.17 Furthermore, recent studies also
showed that serum hepcidin was elevated in H. pylori-
infected patients and the levels were normalised after H.
pylori eradication.18,19
Other Haematological Associations
Several other haematological diseases had also been
associated with H. pylori infection, such as
antiphospholipid syndrome, autoimmune neutropenia,
mucosa-associated lymphoid tissue (MALT) lymphoma,
myelodysplastic syndrome, plasma cell dyscrasias and
Schönlein-Henoch Purpura.8,20 H. pylori infection can
stimulate conditioning of polyclonal B lymphocytes and
gastric MALT lymphoma formation through antibody
production. Although the stomach is normally devoid of
mucosal lymphoid tissue, MALT type acquired tissue can
develop during chronic H. pylori infection.21 However,
except for the MALT lymphoma, the exact mechanism by
which H. pylori is responsible for pathophysiology of
these other diseases is still unclear and might be linked to
the host response against the bacteria-related factors.
Cardiovascular Diseases
Coronary Heart Disease
Coronary heart disease (CHD), or ischaemic heart disease,
is an inadequate blood supply to the myocardial muscles
due to narrowing or obstruction of the coronary arteries
caused by atherosclerosis plaque formation. Many
researchers have investigated epidemiological and
pathophysiological relationship between CHD and H.
pylori infection. Liu et al. performed a meta-analysis by
selecting 26 case-control studies and more than 5,000
myocardial infarction (MI) patients to estimate risk of MI
by H. pylori infection. They verified a significant
relationship between H. pylori infection and an increased
risk of MI, especially in patients of younger age.22 A
retrospective cohort study by Lai et al. randomly selected
17,075 H. pylori-infected participants from Taiwan
National Health Insurance Research Database and for the
comparison group 68,300 participants from the general
population free of H. pylori infection frequency-matched
by age, gender, and index year. They demonstrated that H.
pylori infection significantly increases the risk of acute
coronary syndrome, and the risk of developing coronary
syndrome in H. pylori-infected patients increased with the
presence of any comorbidity.23 However, several
prospective and case-control studies showed that the
association between acute MI and H. pylori infection is
confounded significantly by the presence of other risk
factors, such as hypertension, diabetes etc.24 Such
heterogeneous and conflicting studies make it difficult to
reach a clear conclusion. 
H. pylori infection can stimulate leukocytes to release a
substance which is able to convert circulating fibrinogen
into fibrin, increasing blood coagulation. H. pylori is also
able to interact with platelet glycoprotein Ib, L-selectin
and P-selectinvia binding to von Willebr and factor,
inducing platelet aggregation. Some studies proposed
that H. pylori can cause increased thrombogenesis by
increasing levels of lipids, triglyceride, TNF and IL-6 in the
plasma; subsequently all of these will cause inflammation
and promote clot formation at the site of a previous
atherosclerotic lesion.25 The antibodies against H. pylori
proteins are capable of recognising host proteins located
inside the atherosclerotic plaque triggering an acute
coronary syndrome by destabilising an atherosclerotic
plaque as a result of inflammation.26 Also, H. pylori can
directly invade macrophages and reach the vascular site
away from its primary colonisation site affecting the
vascular wall surface and the cytoplasm of endothelial
cells, which is evident by the presence of H. pylori
deoxyribonucleic acid (DNA) in the atheroma plaques.27 A
study by Rozankovic et al. reported a cross-reaction
between anti-CagA antibodies and peptides of
atherosclerotic carotid arteries. Furthermore, the anti-
CagA antibodies can also recognise antigens located
inside the coronary atherosclerotic plaque of patients
with CHD.28 These studies led to a conclusion that the
infection by H. pylori CagA-positive strains in patients
with classic cardiovascular risk factors increases the risk of
acute coronary syndrome.
Other Vascular Diseases
CagA-positive H. pylori infection association with non-
cardioembolic ischaemic stroke has also been
investigated.29 A study by Wasay et al.30 followed a group
of patients with H. pylori gastritis over a period of time to
identify the risk of non-cardioembolic stroke. In this study,
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the gastritis patients with and without H. pylori infection
were included from the department of Medicine, Aga
Khan University, Karachi. During the two-year follow-up, 3
out of 162 patients (1.85%) with H. pylori-associated
gastritis had stroke. Also, hypertension was more
commonly seen in H. pylori group.30 It is possible that H.
pylori infection might stimulate an increase in IL-18 levels
within carotid artery intima, increasing atherosclerotic
susceptibility. Also, H. pylori activates platelets and can
affect the coagulation process.31 Chen et al. in their study,
concluded that only a small subclass of patients with non-
cardioembolic ischaemic stroke are affected by CagA-
positive H. pylori infection.32 Moreover, many other
studies have shown a potential relationship of H. pylori
infection in the occurrence of pre-eclampsia, a
hypertensive and coagulative disorder.33 Anti-CagA
antibodies are able to recognise β-actin of
cytotrophoblast cells and affect their invasiveness.34
Furthermore, high H. Pylori infection prevalence was
observed in patients with migraine; and after complete H.
pylori eradication, patients showed considerable clinical
improvement.35
Conclusion
Studies conducted over the last decade or so fully
validated the role of H. pylori in some haematological
diseases. Due to these findings, H. pylori eradication is
included in the guidelines for the management of ITP and
IDA. Therefore, we recommend that physicians should
evaluate H. pylori infection status in all patients with
haematological diseases and eradication should be
performed in positive cases. However, the relationship
between H. pylori and cardiovascular diseases is still
unclear. A strong link between coronary heart diseases
and infection with H. pylori CagA+ strains has been
reported, but as CagA is capable of triggering strong host
inflammatory response, there is a possibility of induction
of atherosclerosis and coronary heart disease due to such
chronic inflammatory state. To establish certain role of H.
pylori infection in association with cardiovascular
diseases, more studies are required. However, the
polymorphism in host genetic factors and the
geographical diversity of H. pylori strains must be taken
into consideration before designing these new studies.
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